Publications

  1. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017 Oct 20; 35 (30):3391-3400 Epub 2017 Aug 30
    View PubMed
  2. Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Ocal IT, Pockaj BA. The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review. Am J Surg. 2017 Sep 18 Epub 2017 Sept 18
    View PubMed
  3. Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017 Sep 05 Epub 2017 Sept 05
    View PubMed
  4. Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clin Cancer Res. 2017 Aug 15; 23 (16):4919-4928 Epub 2017 Apr 26
    View PubMed
  5. Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23 (15):4055-4065 Epub 2017 Mar 07
    View PubMed
  6. Vaz-Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider B, Partridge AH. Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer. 2017 Aug 01; 123 (15):2821-2828 Epub 2017 Mar 21
    View PubMed
  7. Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Weinshilboum R, Wang L, Boughey JC. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. J Natl Cancer Inst. 2017 Jul 01; 109: (7).
    View PubMed
  8. Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Res Treat. 2017 Jul; 164 (1):189-199 Epub 2017 Apr 20
    View PubMed
  9. Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW, Schneider BP. Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat. 2017 Jun 23 Epub 2017 June 23
    View PubMed
  10. Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Jun 20; 35 (18):2028-2036 Epub 2017 May 02
    View PubMed
  11. Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92: (5)448-453.
    View PubMed
  12. Heyes R, Northfelt DW, Lott DG. Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management. Otolaryngol Head Neck Surg. 2017 May 01; 194599817707208.
    View PubMed
  13. Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Apr; 15: (2)196-202.e1.
    View PubMed
  14. Padrnos L, Bennett R, Kosiorek H, Dueck AC, Northfelt D, Mikhael J, Tibes R, Khera N, Mesa RA. Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit. J Cancer Educ. 2016 Oct 11;
    View PubMed
  15. Park JW, Liu MC, Yee D, Yau C, van 't Veer, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375: (1)11-22.
    View PubMed
  16. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375: (1)23-34.
    View PubMed
  17. Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Res. 2016 Jul 01; 76 (13):3702-10 Epub 2016 Apr 20
    View PubMed
  18. Tan WW, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Goetz MP, Perez EA. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clin Breast Cancer. 2016 Apr; 16 (2):82-6 Epub 2015 Nov 17
    View PubMed
  19. Moustafa S, Murphy K, Nelluri BK, Northfelt D, Shah P, Lee H, Wilansky S, Naqvi TZ, Meyer S, Mookadam F. Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients. Echocardiography. 2016 Mar; 33: (3)406-15.
    View PubMed
  20. Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clin Cancer Res. 2016 Jan 15; 22 (2):301-9 Epub 2015 Aug 31
    View PubMed
  21. Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM. Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). Clin Cancer Res. 2015 Dec 15; 21: (24)5445-52.
    View PubMed
  22. Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S509-15.
    View PubMed
  23. Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, Anderson KS, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA. Regional recurrence in the era of sentinel lymph node biopsy. Am J Surg. 2015 Dec; 210: (6)1155-60; discussion 1160-1.
    View PubMed
  24. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015 Sep 22; 6: (28)26483-93.
    View PubMed
  25. Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153: (2)435-43.
    View PubMed
  26. Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015 Jul; 99: (Pt A)32-8.
    View PubMed
  27. Padrnos L, Dueck AC, Scherber R, Glassley P, Stigge R, Northfelt D, Mikhael J, Aguirre A, Bennett RM, Mesa RA. Quality of life and disease understanding: impact of attending a patient-centered cancer symposium. Cancer Med. 2015 Jun; 4: (6)800-7.
    View PubMed
  28. Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT, Northfelt DW, Sledge GW Jr. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-blind Clinical Trial of Chemotherapy for Breast Cancer. JAMA Oncol. 2015 Jun; 1(3):369-74.
    View PubMed
  29. Kahn A, Boroff ES, Martin KA, Northfelt DW, Heigh RI. Factitious Disorder in Crohn's Disease: Recurrent Pancytopenia Caused by Surreptitious Ingestion of 6-Mercaptopurine. Case Rep Gastroenterol. 2015 May-Aug; 9: (2)137-41.
    View PubMed
  30. Howe NL, Northfelt DW. A prescription for exercise. Coping With Cancer. 2015 May-Jun; 29(3):28-9.
  31. Safgren SL, Suman VJ, Kosel ML, Gilbert JA, Buhrow SA, Black JL, Northfelt DW, Modak AS, Rosen D, Ingle JN, Ames MM, Reid JM, Goetz MP. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenet Genomics. 2015 Apr; 25: (4)157-63.
    View PubMed
  32. Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J. Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2015 Apr; 56: (4)987-92.
    View PubMed
  33. Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015 Jan; 10: (1)172-80.
    View PubMed
  34. Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15; 20: (18)4747-57.
    View PubMed
  35. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111: (6)1241-8.
    View PubMed
  36. Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014 Aug; 32 (4):710-6 Epub 2014 Apr 18
    View PubMed
  37. Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res. 2014 Jul 15; 20(14):3683-91. Epub 2014 May 07.
    View PubMed
  38. Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, Leuschner C, Alila H, Borad MJ, Ramanathan RK. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother Pharmacol. 2014 May; 73: (5)931-41.
    View PubMed
  39. Ruddy KJ, O'Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, Dang C, Northfelt DW, Sledge GW Jr, Partridge AH. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014 Apr; 144: (3)591-7.
    View PubMed
  40. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, North Central Cancer Treatment Group. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol. 2014 Apr; 37: (2)167-71.
    View PubMed
  41. Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol. 2014 Jan; 9(1):121-5.
    View PubMed
  42. Mookadam F, Sharma A, Lee HR, Northfelt DW. Intersection of cardiology and oncology clinical practices. Front Oncol. 2014; 4:259.
    View PubMed
  43. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol. 2013 Dec; 36: (6)540-4.
    View PubMed
  44. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Oct; 31: (5)1251-6.
    View PubMed
  45. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct; 24: (10)2548-54.
    View PubMed
  46. Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R. Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2013 Oct; 18(5):934-41. Epub 2012 Oct 11
    View PubMed
  47. Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013 Sep 10; 31: (26)3197-204.
    View PubMed
  48. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res. 2013 Sep 01; 19: (17)4816-23.
    View PubMed
  49. Cherington C, Schuster SR, Kundranda M, Valdez R, Mesa RA, Northfelt DW. A surprising cause of masses in the chest. Am J Hematol. 2013 Jun; 88(6):518-21. Epub 2012 Oct 17.
    View PubMed
  50. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013 May; 25(3):218-23.
    View PubMed
  51. Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr; 138: (2)427-35.
    View PubMed
  52. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol. 2013 Apr; 27: (4)657-70.
    View PubMed
  53. Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Feb; 54(2):277-83. Epub 2012 Sep 08.
    View PubMed
  54. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12: (6)387-91.
    View PubMed
  55. Johnson CM, Northfelt DW. Investigating pocket cards to improve cancer patient knowledge of chemotherapy. J Clin Oncol. 2012 Dec; 30: (34_suppl)35.
    View PubMed
  56. Schuster SR, Pockaj BA, Bothe MR, David PS, Northfelt DW. Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: a case report. J Pers Med. 2012 Sep 10; 2: (3)71-6.
    View PubMed
  57. Haakinson DJ, Leeds SG, Dueck AC, Gray RJ, Wasif N, Stucky CC, Northfelt DW, Apsey HA, Pockaj B. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012 Sep; 19(9):3012-8. Epub 2012 Mar 27.
    View PubMed
  58. Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012 May 1; 118(9):2424-30. Epub 2011 Sep 27.
    View PubMed
  59. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  60. Block MS, Suman V, Kosel ML, Markovic S, Northfelt DW, Mukherjee P, McCullough AE, Pockaj BA, Nevala WK, Ingle JN, Perez EA, Gendler SJ. MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. J Clin Oncol. 2011 May 20; 29: (15_suppl)e13046.
    View PubMed
  61. Schneider BP, Li L, Miller K, Flockhart D, Radovich M, Hancock BA, Kassem N, Foroud T, Koller DL, Badve SS, Li Z, Partridge AH, O'Neill AM, Sparano JA, Dang CT, Northfelt DW, Smith ML, Railey E, Sledge GW. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol. 2011 May 20; 29: (15_suppl)1000.
    View PubMed
  62. Ingle JN, Fridley BL, Buzdar A, Robson ME, Kubo M, Liu M, Ibrahim-Zada I, Batzler A, Jenkins GD, Goetz MP, Northfelt DW, Perez EA, Williard CV, Wang L, Schaid DJ, Nakamura Y, Weinshilboum RM. Genes regulating estradiol and estrone-conjugate levels in postmenopausal women with resected early-stage breast cancer detected by a genome-wide association study (GWAS). J Clin Oncol. 2011 May 20; 29: (15_suppl)1001.
    View PubMed
  63. Northfelt DW, Dueck AC, Flynn TP, Zander PJ, Stella PJ, Melnik M, Pavey ES, Perez EA. Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. J Clin Oncol. 2011 May 20; 29: (15_suppl)1126.
    View PubMed
  64. Cohen PA, Northfelt DW, Weiss GJ, Von Hoff DD, Manjarrez K, Dietsch G, Hershberg RM, Ramanathan RK. Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29: (15_suppl)2537.
    View PubMed
  65. Palmer SR, Erlichman C, Fernandez-Zapico M, Qi Y, Almada L, McCleary-Wheeler A, Borad MJ, Molina JR, Grothey A, Pitot HC, Jatoi A, Northfelt DW, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G. Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. J Clin Oncol. 2011 May 20; 29: (15_suppl)3092.
    View PubMed
  66. Marschke RF, Borad MJ, McFarland RW, Alvarez RH, Lim JK, Padgett CS, Von Hoff DD, O'Brien SE, Northfelt DW. Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. J Clin Oncol. 2011 May 20; 29: (15_suppl)3087.
    View PubMed
  67. Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:384-90. Epub 2010 Sep 19.
    View PubMed
  68. Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, Gray RJ, McLaughlin SA, Northfelt DW, Sticca RP, Jakub JW, Perez EA. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010 Sep; 17: (9)2419-26.
    View PubMed
  69. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15; 70: (8)3278-86.
    View PubMed
  70. Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. J Clin Pharmacol. 2010 Mar; 50(3):268-75. Epub 2009 Oct 06.
    View PubMed
  71. Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM Jr, Fuloria J, Flynn PJ, Dentchev T, Loprinzi CL. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2010 Mar; 18: (3)321-8.
    View PubMed
  72. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010 Mar; 21: (3)493-7.
    View PubMed
  73. Apsey H, Roy V, Pockaj B, Northfelt D, Sticca R, Nikcevich DA, Mattar B, Fitch T, Perez EA. Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer." J Clin Oncol. 2009 May 20; 27: (15_suppl)623.
    View PubMed
  74. Reinholz MM, Kitzmann KA, Hobday TJ, Northfelt DW, LaPlant B, Allred JB, Dueck AC, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. J Clin Oncol. 2009 May 20; 27: (15_suppl)11095.
    View PubMed
  75. Cheville AL, Sloan JA, Northfelt DW, Jillella AP, Wong GY, Bearden Iii JD, Liu H, Schaefer PL, Marchello BT, Christensen BJ, Loprinzi CL. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer. 2009 Apr; 17 (4):451-60 Epub 2009 Jan 13
    View PubMed
  76. Roy V, Pockaj BA, Northfelt DW, Allred JB, Liu H, Nikcevich DA, Mattar BI, Perez EA. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. J Clin Oncol. 2008 May 20; 26: (15_suppl)563.
    View PubMed
  77. Curtis KK, Jewell RC, Hartney JT, Griffin PP, Fitch TR, Northfelt DW. Phase I study to characterize pharmacokinetics (PK) of topotecan (T) at 4 mg/m2 administered weekly as a 30-minute IV infusion. J Clin Oncol. 2008 May 20; 26: (15_suppl)13551.
    View PubMed
  78. Fitch TR, Northfelt DW, Griffin PP, Goldston M, Lim JK, Padgett CS, Von Hoff DD, Papadopoulos KP. Phase I clinical trial of quarfloxin administered weeklyx3 of a four week cycle. J Clin Oncol. 2008 May 20; 26: (15_suppl)14667.
    View PubMed
  79. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA. Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). J Clin Oncol. 2008 May 20; 26: (15_suppl)1063.
    View PubMed
  80. Curtis KK, Connolly MK, Northfelt DW. Live, attenuated varicella zoster vaccination of an immunocompromised patient. J Gen Intern Med. 2008 May; 23(5):648-9. Epub 2008 Feb 20.
    View PubMed
  81. Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM Jr, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA, North Central Cancer Treatment Group. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Cancer. 2008 Apr 15; 112(8):1772-9.
    View PubMed
  82. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc. 2008 Feb; 83(2):197-203.
    View PubMed
  83. Kelly SV, Burke RF, Lee KS, Torloni AS, Lee RW, Northfelt D, Fonseca R. Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man. Clin Adv Hematol Oncol. 2008 Feb; 6(2):133-6.
    View PubMed
  84. Okuno S, Delaune R, Sloan J, Foster N, Maurer M, Aubry M, Rowland K, Soori G, Nikcevich D, Kardinal C, Northfelt D, Adjei A. A Phase II Study of Gemcitabine and Epirubicin for the Treatment of Pleural Mesothelioma: A North Central Cancer Treatment Study, N0021 Cancer. 2008; 112:1772 - 1779.
    View PubMed
  85. Cheville A, Sloan J, Northfelt D, Jillella A, Wong G, Bearden J, Liu H, Schaefer P, Marchello B, Christensen B, Loprinzi C. The Efficacy of Lidocaine Patch in the Management of Postsurgical Neuropathic Pain in Patients with Cancer: A Phase III Double-Blind, Crossover Study (N01CB). J Pain Symp Manag. 2008.
    View PubMed
  86. Udhrain A, Skubitz KM, Northfelt DW. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomedicine. 2007; 2(3):345-52.
    View PubMed
  87. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1106-11. Epub 2006 May 26.
    View PubMed
  88. Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Adjei AA, Jett JR. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol. 2006 Jul; 1(6):556-63.
    View PubMed
  89. Moreno-Aspitia A, Hillman DW, Wiesenfeld M, Hobday TJ, Rowland KM, Northfelt DW, Tenner KS, Palmieri FM, Perez EA. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)577.
    View PubMed
  90. Moore BA, Northfelt DW. Structure of a physician assistant (PA)-managed survivorship practice within a multidisciplinary breast clinic. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)6087.
    View PubMed
  91. Curtis KK, Northfelt DW. Demographics and disease processes of patients seeking second medical hematology/oncology opinions at a tertiary care center in the United States. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)16018.
    View PubMed
  92. Hunt KS, Northfelt DW. Incorporating genetic counseling into primary care practice. Resident & Staff Physician. 2006 Apr; 52(4):36-42.
  93. Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, Bridgewater J, Moore M, Cassidy J, Coleman R, Coxon F, Redfern CH, Jones JJ, Hawkins R, Northfelt D, Sreedharan S, Valone F, Carmichael J. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol. 2006 Mar; 17(3):437-42. Epub 2005 Nov 25.
    View PubMed
  94. Curtis KK, Northfelt DW. 74-year-old woman with dyspnea on exertion and anemia. Mayo Clin Proc. 2006 Mar; 81(3):393-6.
    View PubMed
  95. Campbell NE, Garvey PB, Northfelt DW, Leighton JA, Heppell JP. Management of severe gastrointestinal bleeding in a patient with acquired Von Willebrand disease complicating enteropathic-associated T-cell lymphoma. Pract Gastroenterol. 2006; 30(3):76-8.
    View PubMed
  96. Harris TJ, Northfelt DW. Chemotherapy error: practical approaches to increasing patient safety. J Patient Safety. 2005 Dec; 1(4):215-219.
  97. Schild SE, Wong WW, Vora SA, Halyard MY, Northfelt DW, Kogut HL, Wheeler RH. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005 Aug 1; 62(5):1432-7.
    View PubMed
  98. Higgins MJ, Roarke MC, Zarka MA, Lanza LA, Northfelt DW. Successful treatment of metastatic metaplastic breast cancer. J Clin Oncol. 2005 Jun; 23: (16_suppl)848.
    View PubMed
  99. Harris TJ, Northfelt DW. Chemotherapy error: Analysis of an error reporting database, recent case reports, error reduction methods, current reporting systems. J Clin Oncol. 2005 Jun; 23: (16_suppl)6091.
    View PubMed
  100. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol. 2004 Dec; 31(6 Suppl 13):36-52.
    View PubMed
  101. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004; 96:759-69.
    View PubMed
  102. Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Therapy. 2003 Aug; 8(4):279-87.
    View PubMed
  103. Smith RE, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 2003 Jun 16; 88(12):1851-8.
    View PubMed
  104. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61.
    View PubMed
  105. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr, Dornseif BE, Damask MC. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. Journal of Pain & Symptom Management. 2002 May; 23(5):355-68.
    View PubMed
  106. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, DuMond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Classic Papers and Current Comments. 2002; 7:878-84.
    View PubMed
  107. Osoba D, Northfelt DW, Budd DW, Himmelberger D. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001; 19(6):573-80.
    View PubMed
  108. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr. 1999 Nov 1; 22(3):235-46.
    View PubMed
  109. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul; 16(7):2445-51.
    View PubMed
  110. Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1; 17(4):339-44.
    View PubMed
  111. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 Jun 5; 336(23):1641-8.
    View PubMed
  112. Levine AM, Tulpule A, Tessman D, Kaplan L, Giles F, Luskey BD, Scadden DT, Northfelt DW, Silverberg I, Wernz J, Espina B, Von Hoff D. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol. 1997 Mar; 15(3):1094-103.
    View PubMed
  113. Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clinical Pharmacology & Therapeutics. 1997 Mar; 61(3):301-11.
    View PubMed
  114. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997 Feb; 15(2):653-9.
    View PubMed
  115. Northfelt DW. Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma. Oncology. 1997; 11(Suppl 11):21-32.
  116. Northfelt DW. Liposome-encapsulated anthracycline chemotherapy for AIDS-related Kaposi's sarcoma. The AIDS Reader. 1997; 7:201-7.
  117. Northfelt DW, Swift PS, Palefsky JM. Anal neoplasia. Pathogenesis, diagnosis, and management. Hematol Oncol Clin North Am. 1996 Oct; 10(5):1177-87.
    View PubMed
  118. Northfelt DW. Anal neoplasia in persons with HIV infection. AIDS Clin Care. 1996 Aug; 8(8):63-6.
    View PubMed
  119. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996 Jan; 36(1):55-63.
    View PubMed
  120. Northfelt DW. Human papillomavirus-associated malignancies. Opportunistic complications of HIV. 1996; 5:28-36.
  121. Timmerman JM, Northfelt DW, Small EJ. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol. 1995 Jun; 13(6):1391-7.
    View PubMed
  122. Hambleton J, Aragon T, Modin G, Northfelt DW, Sande MA. Outcome for hospitalized patients with fever and neutropenia who are infected with the human immunodeficiency virus. Clin Infect Dis. 1995 Feb; 20(2):363-71.
    View PubMed
  123. Gowdey G, Lipsey LR, Lee R, Jacques C, Northfelt DW. Gingival mass lesions in a patient with HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Jan; 79(1):7-9.
    View PubMed
  124. Northfelt DW, Charlebois ED, Mirda MI, Child C, Kaplan LD, Abrams DI. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jan 1; 8(1):45-50.
    View PubMed
  125. Gowdey G, Lipsey LR, Lee R, Jacques C, Northfelt DW. Clinicopathologic conference: gingival mass lesions in a patient with HIV infection. Oral Surg Oral Med Oral Pathol. 1995; 79:7-9.
  126. Northfelt DW. Treatment of Kaposi's sarcoma. Current guidelines and future perspectives. Drugs. 1994 Oct; 48(4):569-82.
    View PubMed
  127. Gunthel CJ, Northfelt DW. Cancers not associated with immunodeficiency in HIV infected persons. Oncology (Huntington). 1994 Jul; 8: (7)59-64; discussion 64, 67-8, 70.
    View PubMed
  128. Northfelt DW. Cervical and anal neoplasia and HPV infection in persons with HIV infection. Oncology (Huntington). 1994 Jan; 8: (1)33-7; discussion 38-40.
    View PubMed
  129. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15; 119(8):786-93.
    View PubMed
  130. Lipsey LR, Northfelt DW. Anogenital neoplasia in patients with HIV infection. Curr Opin Oncol. 1993 Sep; 5(5):861-6.
    View PubMed
  131. Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis. 1993 Jul; 168(1):112-9.
    View PubMed
  132. Northfelt DW, Sollitto RA, Miller TR, Hollander H. Cytomegalovirus pneumonitis. An unusual cause of pulmonary nodules in a patient with AIDS. Chest. 1993 Jun; 103(6):1918-20.
    View PubMed
  133. Heinic GS, Northfelt DW, Greenspan JS, MacPhail LA, Greenspan D. Concurrent oral cytomegalovirus and herpes simplex virus infection in association with HIV infection. A case report. Oral Surg Oral Med Oral Pathol. 1993 Apr; 75(4):488-94.
    View PubMed
  134. Northfelt DW. Mycobacterium avium complex infection in AIDS: clinical presentation, diagnosis, and current therapy. The AIDS Reader. 1993; 3:40-6.
  135. Duvic M, Kaplan LD, Northfelt DW, Siegel BJ. When AIDS patients get cancer. Patient Care. 1993; 27:77-96.
  136. Northfelt DW. Evaluation and treatment of later manifestations of HIV infection. Prim Care. 1992 Mar; 19(1):57-85.
    View PubMed
  137. Kahn JO, Northfelt DW, Miles SA. AIDS-associated Kaposi's sarcoma. AIDS Clin Rev. 1992; 261-80.
    View PubMed
  138. Northfelt DW, Palefsky JM. Human papillomavirus-associated anogenital neoplasia in persons with HIV infection. AIDS Clin Rev. 1992; 241-59.
    View PubMed
  139. Northfelt DW. AIDS-related Kaposi's sarcoma. AIDSFILE. 1992; 6:1-4.
  140. Northfelt DW, Volberding PA. Rationale for early antiviral therapy for HIV infection. HIV: Advances in Research and Therapy. 1992; 2:18-24.
  141. Northfelt DW, Kaplan LD, Abrams DI. Continuous, low-dose therapy with interferon-alpha for human immunodeficiency virus (HIV)-related immune thrombocytopenic purpura. Am J Hematol. 1991 Nov; 38(3):238-9.
    View PubMed
  142. Kahn J, Northfelt D, Volberding P. Chemotherapy for AIDS-associated Kaposi's sarcoma. Oncology (Huntington). 1991 Oct; 5: (10)57-63; discussion 64, 67.
    View PubMed
  143. Northfelt DW, Kaplan LD. Clinical aspects of AIDS-related non-Hodgkin's lymphoma. Curr Opin Oncol. 1991 Oct; 3(5):872-80.
    View PubMed
  144. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991 Jun; 9(6):929-40.
    View PubMed
  145. Northfelt DW, Kahn JO, Volberding PA. Treatment of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am. 1991 Apr; 5(2):297-310.
    View PubMed
  146. Northfelt DW, Mayer A, Kaplan LD, Abrams DI, Hadley WK, Yajko DM, Herndier BG. The usefulness of diagnostic bone marrow examination in patients with human immunodeficiency virus (HIV) infection. J Acquir Immune Defic Syndr. 1991; 4(7):659-66.
    View PubMed
  147. Northfelt DW, Kaplan LD. Clinical manifestations and treatment of HIV related non-Hodgkin lymphoma. Cancer Surv. 1991; 10:121-33.
    View PubMed
  148. Northfelt DW, Polsky B. Bacteremia in persons with HIV infection. AIDS Clin Rev. 1991; 59-79.
    View PubMed
  149. Northfelt DW, Volberding PA. AIDS-related Kaposi's sarcoma: clinical presentation, biology, and therapy. Advances in Oncology. 1991; 7:9-17.
  150. Northfelt DW, Jacobson MA. Lung cancer in persons with human immunodeficiency virus infection. J Respir Dis. 1991; 7:358.
  151. Northfelt DW. Extrapulmonary pneumocystosis. AIDS Medical Report. 1991; 4:35-41.
  152. Northfelt DW. Human papillomavirus-associated malignancy in patients with HIV infection. AIDS Medical Report. 1991; 4:100-4.
  153. Northfelt DW. Combination antiretroviral therapy for HIV infection. AIDSFILE. 1991; 5:5-7.
  154. Northfelt DW. The Changing Face of AIDS: The Emerging Malignancies. Sande MA ed Current Opinion in Infectious Disease. 1991; 4:198-202.
  155. Northfelt DW, Kaplan LD. AIDS-Associated Non-Hodgkin's Lymphoma. Levine AM ed Current Opinion in Oncology. 1991; 3:872-80.
  156. Northfelt DW, Clement MJ, Safrin S. Extrapulmonary pneumocystosis: clinical features in human immunodeficiency virus infection. Medicine (Baltimore). 1990 Nov; 69: (6)392-8.
    View PubMed
  157. Northfelt DW. Clinical presentation and treatment of AIDS-related Kaposi's sarcoma. AIDS Medical Report. 1990; 3:99-108.
  158. Northfelt DW. Extrapulmonary pneumocystosis. AIDSFILE. 1990; 4:3-4.
  159. Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med. 1989 Sep; 87(3):329-31.
    View PubMed
  160. Northfelt DW, Hayward RA, Shapiro MF. The acquired immunodeficiency syndrome is a primary care disease. Ann Intern Med. 1988 Nov 15; 109(10):773-5.
    View PubMed
  161. Skubitz KM, Northfelt DW, McGowan SE, Hoidal JR. Changes in the cell surface protein composition of human alveolar macrophages induced by smoking. Cancer Res. 1987 Jun 15; 47(12):3072-82.
    View PubMed
  162. Northfelt DW, DeNiro MJ, Epstein S. Hydrogen and carbon isotopic ratios of cellulose nitrate and saponifiable lipid fractions prepared from annual growth rings of California Redwood. Geochim Cosmochim Acta. 1981; 45:1895-8.